MicroRNA 499b (MIR499B)

MicroRNA 499b (MIR499B) is a small, non-coding RNA located in the intronic region of the MYH7B gene, typically expressed in cardiac tissue and other sites[3][1]. MIR499B and its family members, including miR-499a, play central roles in heart development, regeneration, and response to injury. They regulate cardiac transcription factors (such as MEF2 and SRF) and are major modulators of gene expression in cardiomyocytes[1][3]. MIR499B variants (notably rs3746444) have been linked to increased risk for cardiovascular disorders and may alter microRNA maturation and function, ultimately disrupting normal regulation of physiological and pathological processes in the heart and other tissues[3][7]. MIR499B is also implicated in cancer biology as part of molecular classification models for tumor tissues, acting as a co-regulator of gene expression networks[4]. To date, most studies focus on miR-499a; data on MIR499B remain limited, and confusion or overlap in literature between these two closely related miRNAs is common[2]. Validated drugs directly targeting MIR499B are not currently available. There is considerable nomenclature confusion in the literature between MIR499A (miR-499a) and MIR499B (miR-499b). Most functional studies, biomarker associations, and disease links are reported for miR-499a, not miR-499b. Inconsistent annotation and reporting frequently result in conflation of the two. Confirming the specific microRNA and referenced studies is important to avoid data misinterpretation[2][3]. MIR499B is classified as a miRNA (not a receptor, enzyme, transporter, etc.). Direct evidence for MIR499B-specific interacting drugs is lacking; reported disease roles and biomarker potential are inferred from studies on genetic variants and expression profiling. Misspellings and duplicate names (combining MIR499A and MIR499B or "microRNA 499a" for "499b") are common. For clarity and accuracy, be cautious with all listed aliases[2][3]. MIR499B is a valid miRNA but true MIR499B-specific biological and therapeutic data are limited; most information pertains to MIR499A/miR-499a. Nomenclature overlaps ("microRNA 499a, hsa-mir-499b, etc.") may result in incorrect attribution of biological functions and disease associations from MIR499A to MIR499B[2]. If seeking only true MIR499B data, much reported literature may be referencing MIR499A or generic "miR-499" without isoform specificity[2][3].

Other names

hsa-mir-499bmiR-499bmiRNA-499bMIR499BmicroRNA 499a/b (noting potential confusion with 499a)

No approved drugs targeting MIR499B directly; miRNA mimics or inhibitors under research